Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia.

Friedreich's ataxia is a widespread hereditary ataxia type, affecting a minimum of one in every 50,000 individuals. It is c ...

Ataxia is a condition caused by damage in cerebellum, a part of the brain, that leads to poor muscle control affecting movement. In an interview with HT Lifestyle, Dr Aniruddha More, consultant ...

If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability ...

NICE is unable to make a recommendation about the use in the NHS of omaveloxolone for treating Friedreich's ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

A medication used in dogs suffering from osteoarthritis is facing backlash after thousands of patients have experienced ...

NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.